HLUN info just out
Healtheuniverse, Inc. (OTC: HLUN)
Healtheuniverse is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse is benchmarked to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and is developing many therapeutic uses for disease related commercial applications.
Regenerative medicine has the potential to revolutionize medicine by being able to produce human cells of any kind for use in a wide-array of surgical and therapeutic applications. We own 2 patents related to the field of stem cell therapy, which allows the production of stem cells genetically matched to the patient. Because of the economic potential of this industry (the worldwide market for regenerative medicine is estimated reach $500 billion by 2010), clinical initiatives to capture market share through product commercialization are significant.
The Healtheuniverse Product Line will launch with the Euphora Brand which has a potential market size of $15 billion domestically for Plastic, Reconstructive and Cosmetic Surgery. Initial product lines will target the Botox market where sales totaled $564 million last year in the United States alone. Botox, which helps smooth out wrinkles by paralyzing the underlying facial muscles, is generally administered through a needle. Not only is the Healtheuniverse product superior in that it utilizes the patients own cells instead of a toxin it also lasts for the life of the patient instead of the current 3-6 month application.
Additional Euphora Brand commercial applications for cell-based therapeutics include: fat tissue for plastic, reconstructive and cosmetic surgery, myocardial and endothelial vascular tissue for cardiovascular disease, skin cells for dermatological conditions, neural cells for spinal cord injury and other neuro-degenerative diseases, pancreatic cells for diabetes, cartilage and bone cells for arthritis and orthopedic applications.
Healtheuniverse is developing the Adult Stem Cell Research and Development Center in Singapore with an alliance and support from the Economic Development Board of Singapore (EDB). The centers focus is collaborate with other research and development facilities in Asia in preparation for clinical trials.
The EDB Biomedical Sciences Group (EDB BMSG) is responsible for the development of the Biomedical Sciences industry. The BMSG works closely with A*STAR's Biomedical Research Council (BMRC), Bio*One Capital and other agencies to develop human, intellectual, and industrial capital in Singapore , in support of the Biomedical Sciences industry.
Company Contact Information
1171 West San Bernardino Road Suite F
Covina , CA 91722
Tel: (800) 719-7424
Fax: (626) 967-4610
www.healtheuniverse.com
Market Snapshot
Recent stock price:
Market cap:
52-week high:
52-week low:
Shares outstanding:
Float:
Average volume:
Fiscal year end:
$ .13
$15.3MM
$.43
$.001
118MM
3.9MM
129,000 shares
December 31
Market Highlights
Truly Unmet Need with Blockbuster Potential. The Euphora Brand can compete favorably against all existing cosmetic surgery products, including Botox. We project the Company has the potential to launch Euphora for fine lines and wrinkles this year and can quickly penetrate over 2% of the total market. With an estimated cost of $700/patient, we arrive at top-line revenue of approximately $12,900,000 with net profit of $3,870,000 by 2009.
Proprietary adult stem cell and industry-unique commercialization capability.
Healtheuniverse’s technology is derived from fat based adult stem and progenitor cells (non-embryonic)
Healtheuniverse’s technology has multi-lineage forming capabilities – the cells can form bone, vascular, cartilage and adipose.
Multiple news flow from clinical and preclinical programs in 2007/2008
Well Positioned For Potential Partnership. Healtheuniverse is the only pure adult stem cell company preparing for US based Phase 1 clinical studies targeting the plastic surgery and wound care market, both with large market potential.
With Healtheuniverse owning 100% of the commercial rights to the technology, the company is well positioned to attract the attention of large biotech and pharmaceutical companies
*This fact sheet contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties
Set your desire to Eternal Riches, the true riches.
